Aptevo Therapeutics Inc. (APVO)
| Bid | 4.42 |
| Market Cap | 3.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.7M |
| EPS (ttm) | -324.35 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | -0.02 |
| Analyst | Buy |
| Ask | 4.85 |
| Volume | 52,196 |
| Avg. Volume (20D) | 275,040 |
| Open | 4.66 |
| Previous Close | 4.78 |
| Day's Range | 4.35 - 4.71 |
| 52-Week Range | 4.30 - 606.06 |
| Beta | 5.73 |
About APVO
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for APVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
3 weeks ago · accessnewswire.com
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance PlanSEATTLE, WA / ACCESS Newswire / May 22, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares ...
1 month ago · accessnewswire.com
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials Mipletamig triplet combination continues to outperform standard doublet benchmark No cytokine rele...
2 months ago · accessnewswire.com
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of TreatmentAcross two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform d...
